Quantifying low levels of polymorphic impurity in clopidogrel bisulphate by vibrational spectroscopy and chemometrics

Journal of Pharmaceutical and Biomedical Analysis

Volumn 49, Issue 1, 2009, Pages 32-41

  Német, Zoltán ^a   Demeter, Ádám ^a   Pokol, György ^b  

^a GEDEON RICHTER LTD   (Hungary)

^b BUDAPEST UNIVERSITY OF TECHNOLOGY AND ECONOMICS   (Hungary)

Author keywords

Chemometrics; Clopidogrel bisulphate; IR; Quantitative analysis; Raman; Spectroscopy

Indexed keywords

CLOPIDOGREL;

ARTICLE; CHEMOMETRIC ANALYSIS; DRUG FORMULATION; DRUG IMPURITY; INFRARED RADIATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAMAN SPECTROMETRY; SOLID; VIBRATION;

MULTIVARIATE ANALYSIS; POLYMORPHISM, GENETIC; POWDERS; REPRODUCIBILITY OF RESULTS; SPECTROPHOTOMETRY, INFRARED; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SPECTRUM ANALYSIS; SPECTRUM ANALYSIS, RAMAN; TECHNOLOGY, PHARMACEUTICAL; TICLOPIDINE; VIBRATION; X-RAY DIFFRACTION;

EID: 58249141107     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2008.09.042     Document Type: Article

References (46)

1. Haleblian J.K., and McCrone W.C. J. Pharm. Sci 58 (1969) 911-929
2. Threlfall T.L. Analyst 120 (1995) 2435-2460
3. In: Brittain H.G. (Ed). Polymorphism in Pharmaceutical Solids 95 (1999), Marcel Dekker, New York
4. Bernstein J. Polymorphism of Molecular Crystals (2002), Clarendon, Oxford
5. Byrn S., Pfeiffer R., Ganey M., Hoiberg C., and Poochikian G. Pharm. Res. 12 (1995) 945-954
6. Raw A.S., Furness M.S., Gill D.S., Adams R.C., Holcombe Jr. F.O., and Yu L.X. Adv. Drug. Deliv. Rev. 56 (2004) 397-414
7. Food and Drug Administration, Center for Drug Evaluation and Research, Guidance for Industry, ANDAs: Pharmaceutical Solid Polymorphism: Chemistry, Manufacturing, and Controls Information, http://www.fda.gov/cder/guidance/index.htm, 2007, June.
8. Lucas J., and Burgess P. PharmaVoice (2004) 54-57
9. In: Zakrzewski A., and Zakrzewski M. (Eds). Solid State Characterization of Pharmaceuticals (2006), Assa International Inc, Danbury, Connecticut, USA
10. Bugay D.E. Adv. Drug. Deliv. Rev. 48 (2001) 43-65
11. Giron D.A. Thermochim. Acta 248 (1995) 1-59
12. Stephenson G.A., Forbes R.A., and Reutzel-Edens S.-M. Adv. Drug. Deliv. Rev. 48 (2001) 67-90
13. Findlay W.P., and Bugay D.E. J. Pharm. Biomed. Anal. 16 (1998) 921-930
14. Auer M.E., Griesser U.J., and Sawatzki J. J. Mol. Struct. 661-662 (2003) 307-317
15. Vankiersblick T., Vercauteren A., Baeyens W., van der Weken G., Verpoort F., Vergote G., and Remon J.P. Trends Anal. Chem. 21 (2002) 869-877
16. Pelletier M.J. Appl. Spectrosc. 57 (2003) 20A-42A
17. Black D.B., and Lovering E.G. J. Pharm. Pharm. 29 (1977) 684-687
18. Roston D.A., Walters M.C., Rhinebarger R.R., and Ferro L.J. J. Pharm. Biomed. Anal. 11 (1993) 293-300
19. Bugay D.E., Newman A.W., and Findlay W.P. J. Pharm. Biomed. Anal. 15 (1996) 49-61
20. G. Sertsou, S. Agatonovic-Kustrin, T. Rades, Internet J. Vib. Spec. [www.ijvs.com] 3, 5, 5 (1999).
21. Al-Zoubi N., Koundourellis J.E., and Malamataris S. J. Pharm. Biomed. Anal. 29 (2002) 459-467
22. Koradia V., Chawla G., and Bansal A.K. Acta Pharm. 54 (2004) 193-204
23. Campbell Roberts S.N., Williams A.C., Grimsey I.M., and Booth S.W. J. Pharm. Biomed. Anal. 28 (2002) 1135-1147
24. Taylor L.S., and Zografi G. Pharm. Res. 15 (1998) 755-761
25. Langkilde F.W., Sjöblom J., Tekensberg-Hjelte L., and Mrak J. J. Pharm. Biomed. Anal. 15 (1997) 687-696
26. Roggo Y., Chalus P., Maurer L., Lema-Martinez C., Edmond A., and Jent N. J. Pharm. Biomed. Anal. 44 (2007) 683-700
27. Pöllänen K., Häkkinen A., Huhtanen M., Reinikainen S., Karjalainen M., Rantanen J., Louchi-Kultanen M., and Nyström L. Anal. Chim. Acta 544 (2005) 108-117
28. Kipouros K., Kachrimanis K., Nikolakakis I., and Malamataris S. Anal. Chim. Acta 550 (2005) 191-198
29. Krivácsy Z., and Hlavay J. J. Mol. Struct. 349 (1995) 289-292
30. Deeley C.M., Spragg R.A., and Threlfall T.L. Spectrochim. Acta 47A (1991) 1217-1223
31. Tudor A.M., Church S.J., Hendra P.J., Davies M.C., and Melia C.D. Pharm. Res. 10 (1993) 1772-1776
32. Jalsovszky G., Egyed O., Holly S., and Hegedu{combining double acute accent}s B. Appl. Spectrosc. 49 (1995) 1142-1145
33. Pratiwi D., Fawcett J.P., Gordon K.C., and Rades T. Eur. J. Pharm. Biopharm. 54 (2002) 337-341
34. Strachan C.J., Pratiwi D., Gordon K.C., and Rades T. J. Raman Spectrosc. 35 (2004) 347-352
35. De Spiegeleer B., Baert B., Diericx N., Seghers D., Verpoort F., Van Vooren L., Burvenich C., and Slegers G. J. Pharm. Biomed. Anal. 44 (2007) 254-257
36. Tian F., Zhang F., Sandler N., Gordon K.C., McGoverin C.M., Strachan C.J., Saville D.J., and Rades T. Eur. J. Pharm. Biopharm. 66 (2007) 466-474
37. R. Lifshitz-Liron, E. Kovalevski-Ishai, S. Wizel, S. Avhar-Maydan, R. Lidor-Hadas, Polymorphs of clopidogrel hydrogensulfate, WO 03/051362 (18.12.2002).
38. A. Bousquet, B. Castro, J. Saint-Germain, Polymorphic form of clopidogrel hydrogen sulphate US 6504030 (21.06.2002).
39. Uvarov V., and Popov I. J. Pharm. Biomed. Anal. 46 (2008) 676-682
40. Kaminaka S., and Kitagawa T. Appl. Spectrosc. 49 (1995) 685-687
41. Bell S.E.J., Beattie J.R., McGravey J.J., Peters K.L., Sirimuthu N.M., and Speer J. J. Raman Spectrosc. 35 (2004) 409-417
42. Pellow-Jarman M.V., Hendra P.J., and Lehnert R.J. Vibr. Spectrosc. 12 (1996) 257-261
43. D'Orazio M., and Schrader B. J. Raman Spectrosc. 4 (1976) 253-268
44. Wang H., Mann C.K., and Vickers T.J. Appl. Spectrosc. 56 (2002) 1538-1544
45. Hu Y., Wikström H., Byrn S.R., and Taylor L.S. Appl. Spectrosc. 60 (2006) 977-984
46. Food and Drug Administration, Center for Drug Evaluation and Research, Guidance for Industry, ICH Topic Q2B. Validation of analytical procedures: methodology, http://www.fda.gov/cder/Guidance/1320fnl.pdf, November, 1996.